A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


December 22, 2010

Heart Rhythm Disturbances the Same for All Protease Inhibitors

All Norvir (ritonavir)–boosted protease inhibitors (PIs), not just Kaletra or Norvir-boosted Reyataz, can cause heart rhythm disturbances, according to a new analysis by Strategies for Management of Antiretroviral Therapy (SMART) study researchers, published online by the journal AIDS. The data, which contradict the results of other studies that didn't find other PIs to be associated with heart rhythm abnormalities, also suggest that heart rhythm normalizes after discontinuing the meds.

Heart rhythm disturbances can be harmful. In the least less serious cases, they can lead to dizziness, fainting or may not cause any symptoms at all. In the worst cases, they might require a pacemaker or even result in sudden death.

A person’s heart rhythm is measured using a simple machine called an electrocardiograph (ECG). It evaluates the electrical activity of the heart using electrodes applied to the skin. Two measures of concern are the QTc interval and the PR interval. When the QTc interval is shorted, or the PR interval prolonged, an abnormal heart rhythm is diagnosed.

In the past two years, the U.S. Food and Drug Administration (FDA) has warned that two protease inhibitors—Kaletra (lopinavir/ritonavir) and Norvir-boosted Reyataz (atazanavir)—can cause such heart rhythm disturbances. As to whether other protease inhibitors cause similar problems, studies have yielded mixed results. What’s more, it hasn’t been clear whether discontinuing protease inhibitor-based regimens reverses the problem. 

To provide a deeper and better understanding of the problem, Elsayed Soliman, MD, from the Wake Forest School of Medicine in Winston Salem, North Carolina, and his colleagues analyzed data involving 3,719 HIV-positive people who participated in the SMART study. In SMART, participants either went on and stayed on ARV therapy—using either a PI-based regimen or a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen—or delayed therapy until their CD4s fell to 200 and then stopped therapy again if the CD4s went back above 350. This allowed Soliman’s team to look not only at the effects of both drug classes, but also at the effects of starting or stopping various HIV medications.

The average age of SMART participants in the analysis was 44. Just under half were on an NNRTI-based regimen, and 31 percent were taking a Norvir-boosted PI. In those taking a PI, the majority were taking either Kaletra, Norvir-boosted Reyataz or Norvir-boosted Invirase (saquinavir). People on other PI regimens were classified as “other protease.”

When a variety of factors were taken into account, including race, age and blood pressure, there were no differences in QTc or PR intervals between the various PI regimens at either 12 or 24 months after starting treatment. In all cases, however, the QTc was shorter and the PR was longer in those on a PI than in people taking an NNRTI. This confirmed the findings of previous studies that the problem is unique to the PI class of drugs, but it also demonstrated that no single PI is apparently better than any other in this regard.

As for the effects of stopping PI-based therapy, Soliman’s group found that one particular measurement of QTc improved while those measured using another method did not. The results were clearer in regards to the PR interval, which shortened after people stopped taking a PI-based regimen.

The authors state that the clinical significance of their findings is unknown. There were no cases of sudden death that could be attributed to PI use and changes in QTc interval. Moreover, in the average HIV-negative population, even a 20 millisecond (ms) increase in the PR interval is associated with only an 8 percent increase in all-cause mortality. The average increase seen in this study was only 3ms.

For this reason, the authors are recommending further studies to illuminate the biological mechanism by which PIs affect heart rhythm and to tease out any possible effect on clinical health. They conclude: “These results should not limit the use of protease inhibitor/ritonavir regimens when indicated.”

Search: Heart, heart rhythm, QTc, PR interval, protease inhibitor, PI, Norvir, ritonavir, boosted, Reyataz, atazanavir, Kaletra, lopinavir, Invirase, saquinavir

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.